神经内分泌分化
表观遗传学
神经内分泌细胞
乳腺癌
生物
癌症研究
基因沉默
神经内分泌肿瘤
前列腺癌
谱系(遗传)
小RNA
疾病
三苯氧胺
癌症
小鼠乳腺肿瘤病毒
类有机物
Wnt信号通路
医学
体细胞
靶向治疗
PI3K/AKT/mTOR通路
调节器
前列腺
内科学
突变
细胞分化
机制(生物学)
肺癌
作者
Roberto Würth,Tasneem Cheytan,Paul Schwerd‐Kleine,Ewgenija Gutjahr,Elisa Donato,Verena Thewes,Beatrice Charlotte. Tröster,Theresa Mulholland,Torsten Müller,Daria Doncevic,Laura L. Michel,Celina V. Wagner,Polina Y. Kozyulina,Mario Hlevnjak,Marc Zapatka,Julia Bulkescher,Rebecca Weber,Sarah‐Jane Neuberth,Vera Thiel,Thilo Miersch
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2026-10-28
被引量:1
标识
DOI:10.1158/2159-8290.cd-26-1312
摘要
Neuroendocrine differentiation (NED) promotes lineage plasticity and therapy resistance in prostate and lung cancers. Here we identify NED as a route of treatment escape in breast cancer: neuroendocrine features emerged or increased in 22% of progressive cases, predominantly, but not exclusively, in HER2-positive subtype. Using patient-derived, epithelial/neuroendocrine organoid and xenograft models, we map the epigenetic and transcriptional divergence between epithelial and neuroendocrine states arising from a shared mutational background and define a breast cancer neuroendocrine signature. NED involves epigenetic silencing of EpCAM and amplified HER2, while NEUROD1 functions as a master transcriptional regulator of the neuroendocrine fate. NCAM-positive putative circulating tumor cells were detected in patients in whom EpCAM-based detection had failed. Neuroendocrine tumor cells exhibit an FGFR1 dependency associated with NCAM-FGFR1 interaction and mesenchymal FGFR1 splicing. Together, these findings establish NED as a mechanism of escape from HER2-targeted therapy in breast cancer, with implications for disease monitoring and intervention.
科研通智能强力驱动
Strongly Powered by AbleSci AI